Physician profile
John D Vu
NPI 1124050216
$3,410.50
in general payments reported to CMS, 2019-2025
24 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.90 · 2021: $215 · 2022: $127 · 2023: $945 · 2024: $881 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,035.73 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,020.56 | 2023-2025 | |
| Boston Scientific Corporation | $568.91 | 2021-2025 | Watchman Access System, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $351.32 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.46 | 2023-2025 | Jardiance |
| Philips North America LLC | $202.33 | 2023-2025 | Extended Holter |
| Saluda Medical Americas, INC. | $166.31 | 2025 | Evoke |
| Edwards Lifesciences Corporation | $127.39 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $115.80 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.20 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $89.17 | 2024-2025 | Wainua, Farxiga |
| Biotronik INC. | $61.04 | 2025 | Amvia Edge |
| Amgen INC. | $47.24 | 2023-2025 | Repatha, Repatha |
| Cvrx, INC. | $46.90 | 2024 | Barostim Neo System |
| Irhythm Technologies, INC. | $40.46 | 2021-2023 | Zio Xt Patch |
| Merck Sharp & Dohme LLC | $37.52 | 2023 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $29.30 | 2024 | Impella |
| Abbott Laboratories | $29.20 | 2025 | Mitraclip |
| Janssen Pharmaceuticals, INC | $26.04 | 2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $24.93 | 2024 | |
| Daiichi Sankyo INC. | $24.29 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $22.76 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $21.80 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $14.67 | 2025 | Shingrix |
| Davol INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.